[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20%28Unaudited%29) Unaudited financial statements show no revenue, ongoing net losses, and negative working capital, raising going concern doubts. [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance sheets show decreased total assets, liabilities, and stockholders' equity by June 30, 2024. | Metric | June 30, 2024 (Unaudited) | December 31, 2023 | | :-------------------------------- | :------------------------ | :------------------ | | Cash | $92,827 | $10,059 | | Prepaid expenses and other assets | $42,051 | $258,230 | | Total current assets | $134,878 | $268,289 | | Other investment held at fair value | $- | $726,343 | | Property, plant, and equipment | $15,837,456 | $16,407,415 | | Intangible assets | $9,010 | $1,000 | | **Total assets** | **$15,981,344** | **$17,403,047** | | Accounts payable | $4,768,744 | $4,175,220 | | Accrued liabilities | $37,218 | $411,099 | | Common stock payable for EB-5 program | $800,000 | $- | | Due to others | $- | $1,650,000 | | Related party short-term note payable | $165,000 | $- | | Related party line of credit note | $347,695 | $- | | Total current liabilities | $6,118,657 | $6,236,319 | | Long-term related party line of credit note | $- | $201,783 | | **Total liabilities** | **$6,118,657** | **$6,438,102** | | Common stock | $19,017 | $18,476 | | Additional paid-in capital | $59,440,356 | $58,149,938 | | Accumulated deficit | $(49,596,686) | $(47,203,469) | | **Total stockholders' equity** | **$9,862,687** | **$10,964,945** | | **Total liabilities and stockholders' equity** | **$15,981,344** | **$17,403,047** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss significantly decreased for the six months ended June 30, 2024, due to lower operating expenses and a debt extinguishment gain. | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :----------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Revenue | $- | $- | $- | $- | | Total operating expenses | $1,523,887 | $2,986,506 | $3,401,754 | $5,599,129 | | Loss from operations | $(1,523,887) | $(2,986,506) | $(3,401,754) | $(5,599,129) | | Other income (expense) | $80,120 | $(724) | $1,008,537 | $(1,366) | | Loss before income taxes | $(1,443,767) | $(2,987,230) | $(2,393,217) | $(5,600,495) | | Net loss and comprehensive loss | $(1,443,767) | $(2,992,171) | $(2,393,217) | $(5,605,436) | | Net loss per common share basic and diluted | $(0.01) | $(0.02) | $(0.01) | $(0.03) | - The company recognized a significant **gain on extinguishment of debt of $1,008,589** for the six months ended June 30, 2024, compared to no such gain in the prior year[11](index=11&type=chunk) [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity) Stockholders' equity decreased from **$10.96 million** to **$9.86 million** due to net loss, partially offset by stock-based compensation and common stock issuances. | Metric | Balance at December 31, 2023 | Balance at June 30, 2024 | | :------------------------------------------------ | :--------------------------- | :----------------------- | | Common Stock Shares | 184,758,818 | 190,166,318 | | Common Stock Amount | $18,476 | $19,017 | | Additional paid-in capital | $58,149,938 | $59,440,356 | | Accumulated deficit | $(47,203,469) | $(49,596,686) | | Total stockholders' equity | $10,964,945 | $9,862,687 | **Changes for Six Months Ended June 30, 2024:** * Stock-based compensation: $323,219 * Common stock issued in lieu of unpaid cash remuneration and bonus compensation: 2,420,000 shares, valued at $425,920 * Common stock issued for services: 2,987,500 shares, valued at $541,820 * Net loss: $(2,393,217) [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Operating and investing cash outflows decreased, while financing cash inflows decreased, resulting in an overall cash increase of **$82,768**. | Cash Flow Activity | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :-------------------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(850,393) | $(2,078,750) | | Net cash used in investing activities | $(151,192) | $(2,223,129) | | Net cash provided by financing activities | $1,084,353 | $4,394,750 | | Net increase in cash | $82,768 | $92,871 | | Cash, beginning of period | $10,059 | $414,574 | | Cash, end of period | $92,827 | $507,445 | - Net cash used in operating activities decreased by **$1,228,357** for the six months ended June 30, 2024, compared to the same period in 2023[14](index=14&type=chunk) - Net cash used in investing activities decreased by **$2,071,937** for the six months ended June 30, 2024, compared to the same period in 2023[14](index=14&type=chunk) [Notes to the Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) Notes detail business, going concern, accounting policies, assets, related party transactions, equity, compensation, and contingencies. [1. Description of Business and Organization](index=11&type=section&id=1.%20Description%20of%20Business%20and%20Organization) The company, incorporated in 2019, is a federally authorized cannabis entity expanding into other plant-based medicines, with no revenue generated as of June 30, 2024. - Bright Green Corporation was incorporated on April 16, 2019, and its common stock commenced trading on Nasdaq under the symbol **'BGXX'** on May 17, 2022[15](index=15&type=chunk) - The company holds DEA Manufacturing Registration and DEA Importer Registration, allowing it to produce, export, and sell federally legal cannabis for research and pharmaceutical purposes[102](index=102&type=chunk)[103](index=103&type=chunk) - The company is expanding its focus beyond cannabis to include other plant-based medicines like psilocybin, peyote cactus, and opium poppy, having received New Mexico Board of Pharmacy approval for additional Schedule I and II controlled substances in February 2024[105](index=105&type=chunk) - As of June 30, 2024, the Company is a start-up and has not generated any revenue[17](index=17&type=chunk) [2. Going Concern and Basis of Presentation](index=12&type=section&id=2.%20Going%20Concern%20and%20Basis%20of%20Presentation) The company's recurring losses and negative working capital raise substantial doubt about its ability to continue as a going concern. - The company incurred a net loss of **$2,393,217** for the six months

Core Points - Bright Green Corporation is exploring a $15.0 million debt financing to advance commercialization efforts at its DEA-reinspected facility [1] - The company has secured a $3.5 million capital commitment under its existing line of credit, which includes security against its greenhouse facility and a conversion option for the lender [2][3] - The capital commitment will enable Bright Green to pay down existing liabilities and fund the initiation of operations at its Grants, New Mexico facility [3] Financial Details - The line of credit agreement was amended to allow for the conversion of principal and interest into shares at $1.15 per share, with accompanying warrants priced at $0.13 [2] - The warrants allow the purchase of additional shares at $3.00 per share, with an extension of the term by 3 years [2] Company Overview - Bright Green is one of the few companies authorized by the New Mexico Board of Pharmacy and the US government to produce and distribute Schedule 1-V plant-based drugs, including cannabis-related products [4]

Core Insights - Bright Green Corporation has experienced significant industry shifts in 2024, presenting growth opportunities for the company [1] EB-5 Investment Program - The company has confirmed its first three applications through its EB-5 investment program in partnership with Asia Capital Pioneers Group (ACPG), with more than a dozen additional investors beginning the investment process [2] - ACPG recently hosted a successful event with over 100 potential investors, indicating strong interest in the EB-5 program, with future events planned in Dubai, Singapore, and Malaysia [3] Commercialization of Controlled Substances - Bright Green is advancing its initiative to commercialize Schedule I and Schedule II controlled substances in the U.S., having submitted a DEA 2025 quota request for a total of 22 substances [4] - If approved, the company aims to handle 70% of all marijuana and THC production, 70% of mescaline production, and 50% of psilocybin and psilocyn production within the DEA's program [5] Facility and Production Plans - The company is collaborating with CEADL to upgrade its existing facility and prepare for production, with initial production expected by the end of Q1 2025 [6] Internal Developments - Bright Green has decided to establish its own in-house API and Plant Genetics Research and Medical team to leverage Smart Farming and AI technology, enhancing its agility in meeting the demand for controlled substances [9] Cannabis Reclassification - The DEA's initiative to reclassify cannabis as a Schedule III substance is viewed positively by the company, as it is expected to increase demand for cannabis as an active ingredient [10][11] - The company anticipates carrying 70% of the DEA's cannabis quota in the U.S. by 2025, positioning itself as the largest producer of DEA cannabis in the country [11] Strategic Vision - Bright Green aims to pioneer the "Drugs Made in America" movement, focusing on creating a reliable domestic API supply chain and reducing dependence on foreign drug imports [13]

Core Insights - Bright Green Corporation has experienced significant industry shifts in 2024, presenting growth opportunities for the company [1] EB-5 Investment Program - The company has confirmed its first three applications through its EB-5 investment program in partnership with Asia Capital Pioneers Group (ACPG), with more than a dozen additional investors beginning the investment process [2] - ACPG recently hosted a successful event with over 100 potential investors, indicating strong interest in the EB-5 program, with future events planned in Dubai, Singapore, and Malaysia [3] Commercialization of Controlled Substances - Bright Green is advancing its initiative to commercialize Schedule I and Schedule II controlled substances in the U.S., having submitted a DEA 2025 quota request for a total of 22 substances [4] - If approved, the company aims to handle 70% of all marijuana and THC production, 70% of mescaline production, and 50% of psilocybin and psilocyn production within the DEA's program [5] Facility and Production Plans - The company is collaborating with CEADL to upgrade its existing facility and prepare for production, with initial production expected by the end of Q1 2025 [6] Internal Developments - Bright Green has decided to establish its own in-house API and Plant Genetics Research and Medical team to leverage Smart Farming and AI technology, enhancing its agility in meeting the demand for controlled substances [9] Cannabis Reclassification - The DEA's initiative to reclassify cannabis as a Schedule III substance is viewed positively by the company, as it is expected to increase demand for cannabis as an active ingredient [10][11] - The company anticipates carrying 70% of the DEA's cannabis quota in the U.S. by 2025, positioning itself as the largest producer of DEA cannabis in the country [11] Strategic Vision - The company aims to pioneer the "Drugs Made in America" movement, creating a reliable domestic API supply chain and reducing dependence on foreign drug imports [13]

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) Unaudited financial statements present the company's financial position and performance for Q1 2024 and 2023 [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased, liabilities decreased, and stockholders' equity slightly increased by March 31, 2024 | Metric | March 31, 2024 | December 31, 2023 | | :-------------------------------- | :------------- | :---------------- | | Total Assets | $15,956,333 | $17,403,047 | | Total Liabilities | $4,842,780 | $6,438,102 | | Total Stockholders' Equity | $11,113,553 | $10,964,945 | | Cash | $0 | $10,059 | | Other investment held at fair value | $0 | $726,343 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Net loss decreased to $949,450 in Q1 2024, driven by debt extinguishment gain and lower operating expenses | Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :----------------------------------- | :-------------------------------- | :-------------------------------- | | Revenue | $0 | $0 | | Net Loss | $(949,450) | $(2,613,265) | | Net Loss per Common Share | $(0.01) | $(0.02) | | Gain on extinguishment of debt | $1,008,589 | $0 | | Total operating expenses | $1,877,867 | $2,612,623 | [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity) Stockholders' equity increased to $11.11 million by March 31, 2024, from stock-based compensation and common stock issuance | Metric | March 31, 2024 | December 31, 2023 | | :----------------------------------- | :------------- | :---------------- | | Total Stockholders' Equity | $11,113,553 | $10,964,945 | | Common Shares Outstanding | 190,166,318 | 184,758,818 | | Common stock issued for settlement of accounts payable | $425,920 | - | | Common stock issued for services | $541,820 | - | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow shifted to a net use of $58,552 in Q1 2024; cash at period end was $0 | Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :------------------------------------------ | :-------------------------------- | :-------------------------------- | | Net cash (used in) provided by operating activities | $(58,552) | $273,391 | | Net cash used in investing activities | $(61,507) | $(1,537,668) | | Net cash provided by financing activities | $110,000 | $1,272,205 | | Cash, End of Period | $0 | $422,502 | [Notes to the Condensed Consolidated Financial Statements (Unaudited)](index=12&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) Notes detail business, accounting policies, financial instruments, related party transactions, and going concern risks - Company is a start-up with **no revenue** as of March 31, 2024[35](index=35&type=chunk)[60](index=60&type=chunk) - Incurred recurring losses and has an **accumulated deficit of $48,152,919** as of March 31, 2024[60](index=60&type=chunk) - Substantial doubt about the company's ability to continue as a going concern due to insufficient working capital and reliance on additional financing[37](index=37&type=chunk)[82](index=82&type=chunk) - Received DEA Registration for bulk manufacturing of cannabis on April 28, 2023, and a second DEA registration for Importing Schedule I Controlled Substances in May 2023[171](index=171&type=chunk) - Received approval from the New Mexico Board of Pharmacy in February 2024 to produce additional Schedule I and Schedule II controlled substances (e.g., psilocybin, peyote cactus, opium poppy)[201](index=201&type=chunk) - Modified EB-5 Program on March 29, 2024, to authorize **20,000,000 shares** to be sold at **$2.00 per share** for up to 50 investors[56](index=56&type=chunk) - Recognized a **$1,008,589 gain on extinguishment of debt** for Q1 2024 due to a Settlement and Release Agreement[123](index=123&type=chunk) - Total stock-based compensation costs for Q1 2024 were **$672,138**, allocated to general and administrative expenses[141](index=141&type=chunk) - Subsequent event: Received **$749,878** from one accredited investor for the EB-5 Program on April 25, 2024[154](index=154&type=chunk) - Subsequent event: Drew an additional **$60,000** on the related party line of credit in April 2024[197](index=197&type=chunk) [1. Description of Business and Organization](index=12&type=section&id=1.%20Description%20of%20Business%20and%20Organization) Bright Green Corporation, a start-up, holds DEA registrations for cannabis and is expanding into other controlled substances - Incorporated on April 16, 2019, under Delaware General Corporation Law[33](index=33&type=chunk) - Received DEA Registration for bulk manufacturing of cannabis on April 28, 2023, and for Importing Schedule I Controlled Substances in May 2023[171](index=171&type=chunk) - Approved by the New Mexico Board of Pharmacy in February 2024 to produce additional Schedule I and Schedule II controlled substances (e.g., psilocybin, peyote cactus, opium poppy)[201](index=201&type=chunk) - Modified the EB-5 Program on March 29, 2024, to authorize **20,000,000 shares** to be sold at **$2.00 per share** for up to 50 investors[56](index=56&type=chunk) - Formed Regional Center Bright Green, LLC (RCBG) on September 20, 2023, to assist foreign investors with the EB-5 program, but it was not yet operational as of March 31, 2024[57](index=57&type=chunk) - Company is a start-up and has **no revenue** as of March 31, 2024[35](index=35&type=chunk) [2. Going Concern and Basis of Presentation](index=13&type=section&id=2.%20Going%20Concern%20and%20Basis%20of%20Presentation) The company faces significant going concern risks due to recurring losses and negative working capital | Metric | March 31, 2024 | December 31, 2023 | | :------------------- | :------------- | :---------------- | | Accumulated Deficit | $48,152,919 | $47,203,469 | | Negative Working Capital | $4,621,021 | $5,968,030 | | Net Loss (Q1) | $(949,450) | $(2,613,265) | - Substantial doubt about the company's ability to continue as a going concern due to insufficient working capital to pay operating expenses for at least 12 months[37](index=37&type=chunk)[82](index=82&type=chunk) - Company's continued existence depends on its ability to execute its operating plan and obtain additional debt or equity financing[37](index=37&type=chunk) [3. Summary of Significant Accounting Policies](index=14&type=section&id=3.%20Summary%20of%20Significant%20Accounting%20Policies) This section outlines the company's accounting policies, including U.S. GAAP conformity, consolidation, and fair value measurements - Financial statements are prepared in conformity with U.S. GAAP for interim financial information[36](index=36&type=chunk) - The company consolidates the accounts of its wholly-owned subsidiary, Regional Center Bright Green, LLC[65](index=65&type=chunk) - Depreciation of property, plant, and equipment is provided using the declining balance or straight-line method[41](index=41&type=chunk) - Uses a three-level hierarchy for fair value measurements (Level 1, 2, 3)[68](index=68&type=chunk)[90](index=90&type=chunk) - Accounts for stock-based compensation awards under ASC 718, recognizing fair value over the vesting period[98](index=98&type=chunk) - Elected to use the extended transition period for complying with new or revised accounting standards under the JOBS Act[233](index=233&type=chunk) [4. Concentration of Credit Risk](index=21&type=section&id=4.%20Concentration%20of%20Credit

Financial Performance - The company reported a negative operating cash flow of $2,455,612 for the year ended December 31, 2023, compared to a negative cash flow of $2,265,770 for the year ended December 31, 2022[48]. - The company may need to raise substantial additional funds in the future, which may not be available on acceptable terms[45]. - The company’s future earnings and cash flows may be volatile, resulting in uncertainty about its prospects[46]. - There is uncertainty regarding the availability of substantial additional funds needed for future operations[109]. - The company does not intend to pay any dividends in the foreseeable future, focusing instead on retaining earnings to fund business growth[161]. - The company does not anticipate paying any cash dividends on its common stock in the foreseeable future[181]. Stock and Financing - The company has sold 44,010 shares of common stock at $39.99 per share, generating proceeds of $1.76 million as of May 25, 2023[69]. - The company issued 1,000,000 shares of common stock in connection with the merger with Grants Greenhouse Growers, Inc., and received an option to purchase approximately 505 acres of land at $5,000 per acre[70]. - The company modified its private placement offering to authorize the sale of 20,000,000 shares at $2.00 per share under the EB-5 immigrant investor program[143]. - The company initiated its EB-5 Program on February 1, 2023, allowing the issuance of up to 12,609,152 shares of common stock at a price of $39.99 per share, with 44,010 shares issued to date[165]. - The company may need to seek additional financing for future acquisitions or strategic transactions, which could lead to dilution for current stockholders[147]. - The company may issue additional shares of common stock in the future, which could significantly dilute existing stockholders[158]. - The company expects to issue additional shares of common stock or securities convertible into common stock in connection with possible financings or acquisitions, which could result in substantial dilution[203]. - The company has issued warrants and may continue to issue additional securities, which could dilute ownership interest and exert downward pressure on the stock price[204]. Regulatory and Compliance Risks - The company faces risks related to obtaining insurance at economically viable rates due to its involvement in the cannabis industry[78]. - The company is subject to significant regulatory risks, including FDA regulations that could negatively impact its financial condition[45]. - Future FDA regulations could significantly affect the cannabis industry, impacting operational costs and business prospects[94]. - The company is subject to various laws and regulations in different jurisdictions, which may impede expansion and increase operational costs[129]. - The company may face increased legal and financial compliance costs due to changing laws and regulations, potentially diverting management's attention from revenue-generating activities[192]. - The company has identified a material weakness in its internal control over financial reporting as of June 30, 2022, but concluded that its disclosure controls were effective as of December 31, 2023[58]. Market and Industry Conditions - The cannabis markets are heavily reliant on discretionary consumer spending, which may be adversely affected by the current economic environment due to COVID-19 and high volatility[80]. - The U.S. wholesale market for cannabis and other controlled substances for research is of unknown size and difficult to forecast[121]. - Recent enforcement actions by U.S. Customs and Border Protection against state-legal cannabis could disrupt product transport and reduce profitability[141]. - The company faces competition in attracting and retaining research and pharmaceutical customers, which could impact profitability[122]. Operational Challenges - The company is subject to various risks related to construction projects, including delays in obtaining necessary governmental approvals and permits[104]. - Logistical problems and unexpected costs in facility construction could disrupt production schedules and negatively affect financial conditions[105]. - Quality control systems are critical to the success of the business, and any significant failure could adversely affect operations[138]. - The company may face product liability claims that could adversely affect its reputation and financial condition[106]. - The company may experience significant integration challenges and increased costs associated with future acquisitions[170]. Management and Personnel - The company is highly dependent on its management team, and the loss of key personnel could adversely affect its business and growth prospects[50]. - The company is dependent on stable banking relations, which may be affected by banks' risk aversion towards the cannabis industry[144]. - The company is dependent on traditional banking services for its operations, and any loss of banking relationships could adversely affect its business[167]. Cybersecurity and Intellectual Property - The company is susceptible to cyber-security risks, with successful attacks potentially leading to financial losses and reputational damage[150]. - The company faces risks related to intellectual property, including potential litigation to defend its rights, which could be costly and distract management[171]. Stock Market Compliance - The company received notice from Nasdaq granting an additional 180-day grace period until August 12, 2024, to regain compliance with the Bid Price Rule, requiring a minimum bid price of $1.00 for at least 10 consecutive business days[195]. - If the company fails to regain compliance, it may face delisting from Nasdaq, which could negatively affect the market price of its common stock[196]. - The company is classified as an "emerging growth company," allowing it to take advantage of reduced disclosure requirements[183]. - The company may rely on exemptions from certain disclosure requirements as a smaller reporting company, which could affect the attractiveness of its common stock to investors[186].

GRANTS, NEW MEXICO, March 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") Today announced that BGXX will install a 102-megawatt solar field to power the electricity and heating requirements for the new $250 million Dalsem expansion project and commits to switch the existing facility that currently burns natural gas and heavy oil to solar. This ensures that the BGXX production and drug manufacturing requirements in Grants, New Mexico are carbon neutral. T ...

GRANTS, NEW MEXICO, March 12, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") today announced that it has signed an agreement with Dalsem Greenhouse Technologies BV for a $250 million construction project to expand the Company's current research, production and extraction processing facility located in rural Grants, New Mexico (the "Dalsem Agreement"). The proposed expansion will add 7 million square feet of manufacturing and production capabilities. The Dal ...

CEO, Groovy Singh appointed as a new member of the Company's Board Founder, Lynn Stockwell, appointed as Chair of the Board of Directors Grants, New Mexico, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) – Bright Green Corporation, a Delaware corporation (the "Company"), announced Friday that CEO Groovy Singh is the newest member of the company's Board of Directors (the "Board"). Current board member and Co-Founder Lynn Stockwell was also announced as the new Chair of the Board. Si ...

Grants, New Mexico, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) today announced the agreement to purchase assets from C2 Wellness Corporation. ("C2"), a Wyoming registered company with an address at 30 N Gould St, Ste R, Sheridan, WY, that owns certain platform technologies and associated intellectual property invented and developed by the scientific team of C2. The purchase is for 5 million shares of common stock of Bright Green Corporation payable to all shareholders of C2. Th ...